A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Steven C. Plaxe; John A. Blessing; George Olt; Nader Husseinzadah; Samuel S. Lentz; Koen DeGeest; Fidel A. Valea

doi:10.1007/s00280-002-0470-2

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Steven C. Plaxe
, John A. Blessing
, George Olt
, Nader Husseinzadah
, Samuel S. Lentz
, Koen DeGeest
, Fidel A. Valea

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m² was given to the first 11 patients and was reduced to 560 mg/m² for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

Original language	English (US)
Pages (from-to)	151-154
Number of pages	4
Journal	Cancer Chemotherapy and Pharmacology
Volume	50
Issue number	2
DOIs	https://doi.org/10.1007/s00280-002-0470-2
State	Published - 2002
Externally published	Yes

Funding

Acknowledgements This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

Funders	Funder number
Gynecologic Oncology Group Administrative Office	CA 27469
Gynecologic Oncology Group Statistical Office
National Institute of Health-National Cancer Institute	U10CA037517

Keywords

Cervical cancer
PZA
Pyrazoloacridine

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s00280-002-0470-2

Cite this

@article{d8f366a0ba9744119f9e128f422fb1a1,

title = "A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study",

abstract = "Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2\%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.",

keywords = "Cervical cancer, PZA, Pyrazoloacridine",

author = "Plaxe, \{Steven C.\} and Blessing, \{John A.\} and George Olt and Nader Husseinzadah and Lentz, \{Samuel S.\} and Koen DeGeest and Valea, \{Fidel A.\}",

note = "Funding Information: Acknowledgements This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).",

year = "2002",

doi = "10.1007/s00280-002-0470-2",

language = "English (US)",

volume = "50",

pages = "151--154",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "2",

}

TY - JOUR

T1 - A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix

T2 - A gynecologic oncology group study

AU - Plaxe, Steven C.

AU - Blessing, John A.

AU - Olt, George

AU - Husseinzadah, Nader

AU - Lentz, Samuel S.

AU - DeGeest, Koen

AU - Valea, Fidel A.

N1 - Funding Information: Acknowledgements This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

PY - 2002

Y1 - 2002

N2 - Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

AB - Purpose: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. Methods: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. Results: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. Conclusion: PZA at the dose and schedule employed, has insignificant activity in this population.

KW - Cervical cancer

KW - PZA

KW - Pyrazoloacridine

UR - https://www.scopus.com/pages/publications/0036353160

UR - https://www.scopus.com/pages/publications/0036353160#tab=citedBy

U2 - 10.1007/s00280-002-0470-2

DO - 10.1007/s00280-002-0470-2

M3 - Article

C2 - 12172981

AN - SCOPUS:0036353160

SN - 0344-5704

VL - 50

SP - 151

EP - 154

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: A gynecologic oncology group study

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this